Jones Hill Capital’s Relmada Therapeutics RLMD Stock Holding History

Jones Hill Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3M	Buy	3,655,075 +3,312,323	+966%	+$23.1M	5.38%	6
2026 Q1	$2.39M	Buy	+342,752	New	+$1.62M	0.51%	24

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jones Hill Capital's RLMD Position: Q2 2026 in Review

Jones Hill Capital increased its Relmada Therapeutics (RLMD) stake by 966% in Q2 2026, buying an estimated $23.1M and bringing the position to 3,655,075 shares worth $25.3M. The position accounts for 5.38% of the portfolio, ranked #6.

Jones Hill Capital first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Jones Hill Capital held 3,655,075 shares of Relmada Therapeutics worth $25.3M as of Q2 2026.
Jones Hill Capital bought 3,312,323 Relmada Therapeutics shares in Q2 2026, an estimated $23.1M.
Relmada Therapeutics made up 5.38% of Jones Hill Capital's portfolio in Q2 2026, its #6 holding.
Jones Hill Capital first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.